Earnings
Home›Earnings›Analyst Ratings›Pfizer price target set at $32.36 as Street turns more…
Pfizer price target set at $32.36 as Street turns more bullish
The $32.36 target implies about 15.3% upside from Pfizer’s $28.07 close, alongside a 6.19% dividend yield.
Wall Street analysts are leaning toward a rebound in Pfizer, with a $32.36 price target that suggests 15.27% upside from the company’s recent close of $28.07, according to Yahoo Finance. The same view points to a 6.19% dividend yield and a BUY rating, with model confidence cited at 90%.
The article also frames Pfizer’s valuation as a key part of the turnaround case, saying the stock trades at 10 times forward earnings. It compares that multiple with Merck at 18 times and Bristol Myers Squibb at 11 times.
On fundamentals, the piece highlights that Pfizer’s CEO Albert Bourla has beaten revenue consensus in nine of the last ten quarters, and it notes that the company plans 19 pivotal study starts over the next 12 months across oncology, obesity, and immunology.
For recent performance, the article cites Pfizer’s Q2 2026 results reported August 4, including $15 billion in revenue and adjusted diluted EPS of 77 cents, plus a raised revenue guide of $60.5 billion to $62.5 billion. It also mentions a $4.3 billion writedown and points to uncertainty from prior COVID-related declines and expected competition from generics and biosimilars.